# ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

> **NCT01774721** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 452 (actual)

## Conditions studied

- Non-small Cell Lung Cancer With EGFR-Activating Mutations

## Interventions

- **DRUG:** Dacomitinib (PF-00299804)
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT01774721
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-09
- **Primary completion:** 2016-07-29
- **Final completion:** 2022-01-27
- **Target enrollment:** 452 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01774721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01774721, "ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01774721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*